{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:52:33Z","timestamp":1780087953133,"version":"3.54.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40256-017-0213-8","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T06:28:49Z","timestamp":1485498529000},"page":"157-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Pitavastatin: A Review in Hypercholesterolemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"issue":"39","key":"213_CR1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J."},{"issue":"29","key":"213_CR2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J."},{"key":"213_CR3","doi-asserted-by":"crossref","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","DOI":"10.1016\/j.jacc.2013.11.002"},{"issue":"10","key":"213_CR4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.4020","volume":"25","author":"D Thakker","year":"2016","unstructured":"Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131\u201349.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"213_CR5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/11207180-000000000-00000","volume":"72","author":"ST Duggan","year":"2012","unstructured":"Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs. 2012;72(4):565\u201384.","journal-title":"Drugs."},{"key":"213_CR6","unstructured":"Kowa Pharmaceutical Europe Co. Ltd. Pivastatin: UK summary of product characteristics. 2016. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"issue":"4","key":"213_CR7","first-page":"251","volume":"52","author":"Y Saito","year":"2002","unstructured":"Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung. 2002;52(4):251\u20135.","journal-title":"Arzneimittelforschung."},{"key":"213_CR8","unstructured":"Medicines and Healthcare Products Regulatory Agency. Pitavastatin: public assessment report (UK). 2010. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"issue":"12","key":"213_CR9","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1194\/jlr.P061143","volume":"56","author":"PJ Meikle","year":"2015","unstructured":"Meikle PJ, Wong G, Tan R, et al. Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. J Lipid Res. 2015;56(12):2381\u201392.","journal-title":"J Lipid Res."},{"issue":"2","key":"213_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2015.194","volume":"12","author":"DJ Betteridge","year":"2016","unstructured":"Betteridge DJ, Carmena R. The diabetogenic action of statins: mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99\u2013110.","journal-title":"Nat Rev Endocrinol."},{"key":"213_CR11","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.2147\/DDDT.S87979","volume":"9","author":"W Zhao","year":"2015","unstructured":"Zhao W, Zhao S-P. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Dev Ther. 2015;9:6211\u201323.","journal-title":"Drug Des Dev Ther."},{"key":"213_CR12","doi-asserted-by":"crossref","first-page":"314170","DOI":"10.1155\/2013\/314170","volume":"2013","author":"H Kakuda","year":"2013","unstructured":"Kakuda H, Kobayashi J, Nakato M, et al. Short-term effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol. 2013;2013:314170.","journal-title":"Cholesterol."},{"issue":"1","key":"213_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2007.08.013","volume":"122","author":"S Nomura","year":"2008","unstructured":"Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39\u201345.","journal-title":"Thromb Res."},{"issue":"1","key":"213_CR14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s11883-014-0472-7","volume":"17","author":"DC Chan","year":"2015","unstructured":"Chan DC, Pang J, Watts GF. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10? Curr Atheroscler Rep. 2015;17(1):472.","journal-title":"Curr Atheroscler Rep."},{"issue":"Suppl 1","key":"213_CR15","first-page":"110","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Sponseller C, Backes J, et al. Pitavastatin lower plasma levels of CoQ10 less than equipotent doses of rosuvastatin or atorvastatin [abstract no. P717]. Eur Heart J. 2016;37(Suppl 1):110.","journal-title":"Eur Heart J."},{"issue":"5","key":"213_CR16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","volume":"19","author":"N Kavalipati","year":"2015","unstructured":"Kavalipati N, Shah J, Ramakrishan A, et al. Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015;19(5):554\u201362.","journal-title":"Indian J Endocrinol Metab."},{"issue":"4","key":"213_CR17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2125.2011.04139.x","volume":"73","author":"J Davignon","year":"2012","unstructured":"Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol. 2012;73(4):518\u201335.","journal-title":"Br J Clin Pharmacol."},{"key":"213_CR18","unstructured":"Kowa Pharmaceuticals America Inc. LIVALO\u00ae (pitavastatin) tablet, for oral use: US prescribing information. 2016. http:\/\/www.fda.gov\/ . Accessed 22 Dec 2016."},{"issue":"3","key":"213_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","volume":"11","author":"AL Catapano","year":"2010","unstructured":"Catapano AL. Pitavastatin: pharmacological profile from early phase studies. Atheroscler Suppl. 2010;11(3):3\u20137.","journal-title":"Atheroscler Suppl."},{"issue":"8","key":"213_CR20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1185\/03007995.2011.589433","volume":"27","author":"A Corsini","year":"2011","unstructured":"Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins\u2019 Achilles\u2019 heel? Curr Med Res Opin. 2011;27(8):1551\u201362.","journal-title":"Curr Med Res Opin."},{"issue":"8","key":"213_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5414\/CP202195","volume":"53","author":"M Gosho","year":"2015","unstructured":"Gosho M, Tanahashi M, Hounslow N, et al. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data. Int J Clin Pharmacol Ther. 2015;53(8):635\u201346.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"8","key":"213_CR22","first-page":"709","volume":"36","author":"Y Kurihara","year":"2008","unstructured":"Kurihara Y, Kawakita K, Douzono T, et al. A large-scale, long-term prospective post-marketing surveillance of pitavastatin (LIVALO\u00ae tablet): LIVALO Effectiveness and Safety (LIVES) study. Jpn Pharmacol Ther. 2008;36(8):709\u201331.","journal-title":"Jpn Pharmacol Ther."},{"issue":"3","key":"213_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/clp.09.20","volume":"4","author":"D Budinski","year":"2009","unstructured":"Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4(3):291\u2013302.","journal-title":"Clin Lipidol."},{"issue":"11","key":"213_CR24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1463-1326.2011.01477.x","volume":"13","author":"J Gumprecht","year":"2011","unstructured":"Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4\u00a0mg and atorvastatin 20\u201340\u00a0mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047\u201355.","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"213_CR25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12325-011-0056-7","volume":"28","author":"M Eriksson","year":"2011","unstructured":"Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011;28(9):811\u201323.","journal-title":"Adv Ther."},{"issue":"11","key":"213_CR26","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1185\/03007990903290886","volume":"25","author":"L Ose","year":"2009","unstructured":"Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755\u201364.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"213_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2047487312451251","volume":"20","author":"S Stender","year":"2013","unstructured":"Stender S, Budinski D, Gosho M, et al. Pitavastatin shows greater lipid-lowering efficacy over 12\u00a0weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013;20(1):40\u201353.","journal-title":"Eur J Prev Cardiol."},{"issue":"3","key":"213_CR28","first-page":"323","volume":"11","author":"PJ Neuvonen","year":"2010","unstructured":"Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010;11(3):323\u201332.","journal-title":"Curr Opin Investig Drugs."},{"issue":"3","key":"213_CR29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705.","journal-title":"Br J Pharmacol."},{"issue":"8","key":"213_CR30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.clinthera.2014.06.009","volume":"36","author":"CA Sponseller","year":"2014","unstructured":"Sponseller CA, Morgan RE, Kryzhanovski VA, et al. Comparison of the lipid-lowering effects of pitavastatin 4\u00a0mg versus pravastatin 40\u00a0mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014;36(8):1211\u201322.","journal-title":"Clin Ther."},{"issue":"10","key":"213_CR31","doi-asserted-by":"crossref","first-page":"e76298","DOI":"10.1371\/journal.pone.0076298","volume":"8","author":"P-Y Liu","year":"2013","unstructured":"Liu P-Y, Lin L-Y, Lin H-J, et al. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One. 2013;8(10):e76298.","journal-title":"PLoS One."},{"issue":"2","key":"213_CR32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0021-9150(01)00712-2","volume":"162","author":"Y Saito","year":"2002","unstructured":"Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162(2):373\u20139.","journal-title":"Atherosclerosis."},{"issue":"6","key":"213_CR33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","volume":"75","author":"K Saku","year":"2011","unstructured":"Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493\u2013505.","journal-title":"Circ J."},{"issue":"11","key":"213_CR34","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.clinthera.2007.11.002","volume":"29","author":"SH Lee","year":"2007","unstructured":"Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29(11):2365\u201373.","journal-title":"Clin Ther."},{"issue":"2","key":"213_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"K Yokote","year":"2008","unstructured":"Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345\u201352.","journal-title":"Atherosclerosis."},{"issue":"1","key":"213_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2047487312437326","volume":"20","author":"S Stender","year":"2013","unstructured":"Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013;20(1):29\u201339.","journal-title":"Eur J Prev Cardiol."},{"issue":"9","key":"213_CR37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12325-011-0057-6","volume":"28","author":"M Eriksson","year":"2011","unstructured":"Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther. 2011;28(9):799\u2013810.","journal-title":"Adv Ther."},{"issue":"1","key":"213_CR38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2009.12.009","volume":"210","author":"L Ose","year":"2010","unstructured":"Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210(1):202\u20138.","journal-title":"Atherosclerosis."},{"issue":"6","key":"213_CR39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5551\/jat.E581","volume":"15","author":"H Koshiyama","year":"2008","unstructured":"Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15(6):345\u201350.","journal-title":"J Atheroscler Thromb."},{"issue":"6","key":"213_CR40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.clinthera.2008.05.017","volume":"30","author":"J Sasaki","year":"2008","unstructured":"Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089\u2013101.","journal-title":"Clin Ther."},{"issue":"9","key":"213_CR41","first-page":"789","volume":"39","author":"T Teramoto","year":"2011","unstructured":"Teramoto T, Urashima M, Shimano H, et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia. Jpn Pharmacol Ther. 2011;39(9):789\u2013803.","journal-title":"Jpn Pharmacol Ther."},{"issue":"4","key":"213_CR42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"T Hiro","year":"2009","unstructured":"Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293\u2013302.","journal-title":"J Am Coll Cardiol."},{"key":"213_CR43","unstructured":"Shiba T, Sakamoto K, Kishimoto J, et al. Beneficial effect of pitavastatin on the incidence of diabetes in lean subjects with IGT: subanalysis of J-PREDICT [abstract no. 1199-P]. In: 75th Annual Scientific Sessions of the American Diabetes Association. 2015."},{"key":"213_CR44","unstructured":"Terauchi Y, Yamazaki T, Kishimoto J, et al. Differential impact of pitavastatin on the incidence of diabetes in patients with or without hypertension: sub-analysis of J-PREDICT [abstract no. 1052-P]. In: 74th Annual Scientific Sessions of the American Diabetes Association. 2014."},{"key":"213_CR45","unstructured":"Odawara M, Yamazaki T, Kishimoto J, et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance [abstract no. 61-LB]. In: 73rd Annual Scientific Sessions of the American Diabetes Association. 2013."},{"key":"213_CR46","unstructured":"Odawara M, Yamazaki T, Kishimoto J, et al. Pitavastatin reduced C-reactive protein without increasing the incidence of diabetes in Japanese individuals with impaired glucose tolerance (J-PREDICT study) [abstract no. P2275]. Eur Heart J. 2014;35(Abstract Suppl):392."},{"key":"213_CR47","unstructured":"Odawara M, Yamazaki T, Kishimoto J, et al. Effect of pitavastatin on the incidence of diabetes in Japanese individuals with impaired glucose tolerance [abstract no. 128]. In: 49th Annual Meeting of the European Association for the Study of Diabetes. 2013."},{"key":"213_CR48","unstructured":"Shiba T, Sakamoto K, Ito C, et al. Beneficial effect of pitavastatin on the incidence of diabetes in women was not associated with age: sub-analysis of J-PREDICT [abstract no. 272]. In: 50th Annual Meeting of the European Association for the Study of Diabetes. 2014."},{"issue":"2","key":"213_CR49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","volume":"241","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409\u201318.","journal-title":"Atherosclerosis."},{"issue":"3","key":"213_CR50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s13340-011-0032-0","volume":"2","author":"T Yamazaki","year":"2011","unstructured":"Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2(3):134\u201340.","journal-title":"Diabetol Int."},{"key":"213_CR51","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2016. http:\/\/www.clinicaltrials.gov\/ . Accessed 22 Dec 2016."},{"issue":"3","key":"213_CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5551\/jat.E1008","volume":"16","author":"K Yokote","year":"2009","unstructured":"Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb. 2009;16(3):297\u20138.","journal-title":"J Atheroscler Thromb."},{"issue":"5","key":"213_CR53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5551\/jat.E562","volume":"15","author":"T Yamakawa","year":"2008","unstructured":"Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15(5):269\u201375.","journal-title":"J Atheroscler Thromb."},{"issue":"5","key":"213_CR54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erc.11.47","volume":"9","author":"K Yokote","year":"2011","unstructured":"Yokote K, Shimano H, Urashima M, et al. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5):555\u201362.","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"5","key":"213_CR55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1185\/03007995.2013.874989","volume":"30","author":"MJ Chapman","year":"2014","unstructured":"Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin. 2014;30(5):775\u201384.","journal-title":"Curr Med Res Opin."},{"key":"213_CR56","unstructured":"Kowa Pharmaceutical Europe Co. Ltd. Kowa announces successful EU regulatory application for pitavastatin. 2010. http:\/\/www.kowapharmaceuticals.eu\/ . Accessed 22 Dec 2016."},{"issue":"9841","key":"213_CR57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565\u201371.","journal-title":"Lancet."},{"key":"213_CR58","doi-asserted-by":"crossref","first-page":"205031211560551","DOI":"10.1177\/2050312115605518","volume":"3","author":"RD Beckett","year":"2015","unstructured":"Beckett RD, Schepers SM, Gordon SK. Risk of new-onset diabetes associated with statin use. SAGE Open Med. 2015;3:2050312115605518.","journal-title":"SAGE Open Med."},{"issue":"9","key":"213_CR59","doi-asserted-by":"crossref","first-page":"e74341","DOI":"10.1371\/journal.pone.0074341","volume":"8","author":"PJ Meikle","year":"2013","unstructured":"Meikle PJ, Wong G, Barlow CK, et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS One. 2013;8(9):e74341.","journal-title":"PLoS One."},{"key":"213_CR60","unstructured":"Pfizer Ireland Pharmaceuticals. Atorvastatin: UK summary of product characteristics. 2013. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"key":"213_CR61","unstructured":"AstraZeneca UK Ltd. Rosuvastatin: UK summary of product characteristics. 2016. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"key":"213_CR62","unstructured":"Merck Sharp & Dohme Limited. Simvastatin: UK summary of product characteristics. 2015. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"key":"213_CR63","unstructured":"Bristol Myers Squibb Pharmaceuticals Limited. Pravastatin: UK summary of product characteristics. 2014. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."},{"key":"213_CR64","unstructured":"Novartis Pharmaceuticals UK Ltd. Fluvastatin: UK summary of product characteristics. 2016. http:\/\/www.mhra.gov.uk\/ . Accessed 22 Dec 2016."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0213-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-017-0213-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-017-0213-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T01:10:11Z","timestamp":1568769011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-017-0213-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1007\/s40256-017-0213-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]}}}